Sintilimab after surgery for node-positive esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove esophageal cancer within the past 4 to 12 weeks.
- Your cancer had spread to lymph nodes (node-positive) but not to distant organs.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have adequate blood cell counts and liver/kidney function.
- You do not have active autoimmune disease, hepatitis B or C, or HIV.
- You have not had other cancer treatments after surgery (like chemo or radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests giving the immunotherapy drug sintilimab together with chemotherapy before and after surgery for esophageal squamous cell carcinoma. It aims to see if this combination can help improve outcomes for patients whose tumors can be surgically removed.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
This Phase 3 trial studies whether adding sintilimab (an immunotherapy medicine) after surgery improves outcomes for people with locally advanced esophageal squamous cell carcinoma. It compares sintilimab plus a chemo/RT plan versus the same chemo/RT plan without immunotherapy.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.